NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: PARNAXLAB · data 2026-10-31
Parnax Lab Limited
In plain words
Price: 26.8% below its 52-week high of ₹149.5.
Delivery: 85.3% of traded shares were kept for delivery over the last 10 sessions, against 83.9% over the last 52.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹252 cr |
| Net profit (last 12 months) | ₹9 cr |
| Sales growth, 3 years (yearly) | 14.0% |
| Profit growth, 3 years (yearly) | 11.0% |
At a glance
P/E 14.1, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 13.2%, ROCE 18.0%, operating margin 6.3%: how much profit it earns on the money it uses.
Debt/equity 0.87, Profit growth 11.0% and sales growth 14.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 83.0% over the last 20 sessions vs 83.0% in the 40 before (1x); shares delivered per day 0.21x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Parnax Lab Limited debt-free?
Its latest reported debt-to-equity ratio is 0.87.
What is Parnax Lab Limited's P/E ratio?
About 14.1, based on the last 12 months' earnings and a price of ₹109.5 (data 2026-10-31).
What is the 52-week high and low of Parnax Lab Limited?
The 52-week high is ₹149.5 and the 52-week low is ₹90.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Parnax Lab Limited | ₹109.5 | ₹122 cr | 14.1 | — | 13.2% | 18% | 0.87 | +1.4% |
| Quest Laboratories Ltd. | ₹82 | ₹134 cr | 9 | 1.4 | 16.7% | 19.3% | 0.08 | -6.8% |
| Bal Pharma Limited | ₹81.85 | ₹129 cr | 18.1 | — | 7.9% | 19.2% | 2.03 | -2.4% |
| Krebs Biochemicals & Industries Ltd. | ₹56.6 | ₹126 cr | — | — | — | -17.3% | — | -18.6% |
| Sotac Pharmaceuticals Limited | ₹111.65 | ₹123 cr | 21.4 | 2.1 | 10.3% | 17.4% | 0.64 | -6.1% |
| Makers Laboratories Ltd | ₹200.9 | ₹119 cr | 34.7 | — | 3.3% | 7.3% | 0.08 | +22.1% |
Compare PARNAXLAB with QUESTLAB in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PARNAXLAB in NSE Scanner →